These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2923807)

  • 1. In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma.
    Millar BC; Bell JB; Maitland JA; Zuiable A; Gore ME; Selby PJ; McElwain TJ
    Br J Haematol; 1989 Feb; 71(2):213-22. PubMed ID: 2923807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.
    Bell JB; Millar BC; Montes-Borinaga A; Joffe JK; Cunningham D; Mansi J; Treleaven J; Viner C; McElwain TJ
    Hematol Oncol; 1990; 8(6):347-53. PubMed ID: 2286358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.
    Maitland JA; Millar BC; Bell JB; Montes A; Treleaven J; Gore ME; McElwain TJ
    Br J Cancer; 1990 Mar; 61(3):429-33. PubMed ID: 2328211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro.
    Borinaga AM; Millar BC; Bell JB; Joffe JK; Millar JL; Gooding R; Riches P; McElwain TJ
    Br J Haematol; 1990 Dec; 76(4):476-83. PubMed ID: 2265109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
    McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colony stimulating activity in the serum of patients with multiple myeloma is enhanced by interleukin 3: a possible role for interleukin 3 after high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
    Millar BC; Bell JB; Montes A; Millar JL; Maitland JA; Treleaven J; Viner C; Gore M; McElwain TJ
    Br J Haematol; 1990 Jul; 75(3):366-72. PubMed ID: 2201402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
    Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
    Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma.
    Raje N; Powles R; Kulkarni S; Milan S; Middleton G; Singhal S; Mehta J; Millar B; Viner C; Raymond J; Treleaven J; Cunningham D; Gore M
    Br J Haematol; 1997 Apr; 97(1):153-60. PubMed ID: 9136958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
    Salmon SE; Dalton WS; Grogan TM; Plezia P; Lehnert M; Roe DJ; Miller TP
    Blood; 1991 Jul; 78(1):44-50. PubMed ID: 1676918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.
    Millar BC; Bell JB; Barfoot R; Everard M
    Br J Cancer; 1995 Feb; 71(2):259-64. PubMed ID: 7841038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors with high-dose melphalan for refractory multiple myeloma.
    Barlogie B; Alexanian R; Smallwood L; Cheson B; Dixon D; Dicke K; Cabanillas F
    Blood; 1988 Dec; 72(6):2015-9. PubMed ID: 3196876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.
    Forgeson GV; Selby P; Lakhani S; Zulian G; Viner C; Maitland J; McElwain TJ
    Br J Cancer; 1988 Oct; 58(4):469-73. PubMed ID: 3207601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells.
    Wyler B; Shao Y; Schneider E; Cianfriglia M; Scheper RJ; Frey BM; Gieseler F; Schmid L; Twentyman PR; Lehnert M
    Br J Haematol; 1997 Apr; 97(1):65-75. PubMed ID: 9136943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro.
    Millar BC; Bell JB; Lakhani A; Ayliffe MJ; Selby PJ; McElwain TJ
    Br J Haematol; 1988 Jun; 69(2):197-203. PubMed ID: 3390392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
    Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
    J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
    Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase in clonogenic tumour cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicin, and methylprednisolone.
    Bell JB; Millar BC; Maitland JA; Nandi A; Gore M; McElwain TJ
    Lancet; 1988 Oct; 2(8617):931-3. PubMed ID: 2902382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.
    Alberts DS; Salmon SE
    Cancer Chemother Rep; 1975; 59(2 Pt 1):345-50. PubMed ID: 1097093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VBAMDex chemotherapy in advanced multiple myeloma.
    Peest D; Schmoll HJ; Schedel I; Glück S; Schumacher K; Deicher H
    Eur J Haematol; 1988 Mar; 40(3):245-9. PubMed ID: 3356240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.